All Stories

  1. Optimizing Clinical Study Designs for CAR ‐T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design

    Article • CPT Pharmacometrics & Systems Pharmacology, July 2026, Wiley

    Robin Michelet

  2. Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization

    Article • Clinical Pharmacology & Therapeutics, December 2025, Wiley

    Robin Michelet

  3. The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization

    Article • Journal of Antimicrobial Chemotherapy, November 2025, Oxford University Press (OUP)

    Robin Michelet

  4. Author’s Reply to Helsby and Hannam: ‘Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical Insights’

    Article • Clinical Pharmacokinetics, August 2025, Springer Science + Business Media

    Robin Michelet

  5. Predicting Residual 21‐Hydroxylase Enzymatic Activity in Pediatric and Adult Congenital Adrenal Hyperplasia Patients: Towards Individualized Therapy

    Article • CPT Pharmacometrics & Systems Pharmacology, July 2025, Wiley

    Robin Michelet

  6. Evaluation of the need for dosing adaptations in obese patients for surgical antibiotic prophylaxis: a model-based analysis of cefazolin pharmacokinetics

    Article • British Journal of Anaesthesia, April 2025, Elsevier

    Robin Michelet

  7. A Pooled Pharmacokinetic Analysis for Piperacillin/Tazobactam Across Different Patient Populations: From Premature Infants to the Elderly

    Article • Clinical Pharmacokinetics, December 2024, Springer Science + Business Media

    Robin Michelet

  8. A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody

    Article • CPT Pharmacometrics & Systems Pharmacology, December 2024, Wiley

    Robin Michelet

  9. Straightforward Phase I Dose-Finding Design for Healthy Volunteers Accounting for Surrogate Activity Biomarkers

    Article • Statistics in Biopharmaceutical Research, December 2024, Taylor & Francis

    Robin Michelet

  10. Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical Insights

    Article • Clinical Pharmacokinetics, October 2024, Springer Science + Business Media

    Robin Michelet

  11. Modeling and Simulations in Latin-American Generic Markets: Perspectives from Chilean Local Industry, Regulatory Agency, and Academia

    Article • Molecular Pharmaceutics, October 2024, American Chemical Society (ACS)

    Dr Miguel Ángel Cabrera-Pérez, Robin Michelet

  12. Exploring the Impact of Developmental Clearance Saturation on Propylene Glycol Exposure in Adults and Term Neonates Using Physiologically Based Pharmacokinetic Modeling

    Article • The Journal of Clinical Pharmacology, October 2024, Wiley

    Professor karel allegaert , Robin Michelet

  13. A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy

    Article • Journal of Pharmacokinetics and Pharmacodynamics, July 2024, Springer Science + Business Media

    Robin Michelet

  14. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial

    Article • Cancer Chemotherapy and Pharmacology, June 2024, Springer Science + Business Media

    Robin Michelet

  15. Personalized Dosing of Medicines for Children: A Primer on Pediatric Pharmacometrics for Clinicians

    Article • Pediatric Drugs, May 2024, Springer Science + Business Media

    Professor karel allegaert , Robin Michelet

  16. Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort

    Article • Clinical Pharmacology & Therapeutics, March 2024, Wiley

    Robin Michelet

  17. Bayesian framework for multi-source data integration-Application to human extrapolation from preclinical studies

    Article • Statistical Methods in Medical Research, March 2024, SAGE Publications

    Robin Michelet

  18. C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework

    Article • Cancers, November 2023, MDPI AG

    Robin Michelet

  19. Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data

    Article • Clinical Pharmacokinetics, August 2023, Springer Science + Business Media

    Robin Michelet

  20. Barriers to global pharmacometrics: educational challenges and opportunities across the globe

    Article • CPT Pharmacometrics & Systems Pharmacology, March 2023, Wiley

    Robin Michelet

  21. Model-Informed Target Morning 17α-Hydroxyprogesterone Concentrations in Dried Blood Spots for Pediatric Congenital Adrenal Hyperplasia Patients

    Article • Pharmaceuticals, March 2023, MDPI AG

    Robin Michelet

  22. Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach

    Article • Frontiers in Pharmacology, January 2023, Frontiers

    Robin Michelet

  23. Microdialysis of Voriconazole and its N-Oxide Metabolite: Amalgamating Knowledge of Distribution and Metabolism Processes in Humans

    Article • Pharmaceutical Research, October 2022, Springer Science + Business Media

    Robin Michelet

  24. Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion

    Article • Clinical Pharmacokinetics, October 2022, Springer Science + Business Media

    Robin Michelet

  25. Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review

    Article • Pharmaceutics, September 2022, MDPI AG

    Robin Michelet

  26. Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N-oxide

    Article • Pharmaceutical Research, September 2022, Springer Science + Business Media

    Robin Michelet

  27. The Impact of Low Cardiac Output on Propofol Pharmacokinetics across Age Groups—An Investigation Using Physiologically Based Pharmacokinetic Modelling

    Article • Pharmaceutics, September 2022, MDPI AG

    Professor karel allegaert , Robin Michelet

  28. The Impact of Low Cardiac Output on Propofol Pharmacokinetics across Age Groups - an Investigation using Physiologically based Pharmacokinetic Modelling

    Article • August 2022, MDPI AG

    Professor karel allegaert , Robin Michelet

  29. High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients

    Article • Antimicrobial Agents and Chemotherapy, June 2022, ASM Journals

    Robin Michelet

  30. Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools

    Article • Antibiotics, June 2022, MDPI AG

    Robin Michelet

  31. Exploring Dried Blood Spot Cortisol Concentrations as an Alternative for Monitoring Pediatric Adrenal Insufficiency Patients: A Model-Based Analysis

    Article • Frontiers in Pharmacology, March 2022, Frontiers

    Oliver Blankenstein, Robin Michelet

  32. Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism

    Article • Pharmaceutics, February 2022, MDPI AG

    Robin Michelet

  33. Combination of Pharmacokinetic and Pathogen Susceptibility Information To Optimize Meropenem Treatment of Gram-Negative Infections in Critically Ill Patients

    Article • Antimicrobial Agents and Chemotherapy, February 2022, ASM Journals

    Robin Michelet

  34. A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices for biomedical applications

    Article • Journal of Pharmaceutical and Biomedical Analysis, February 2022, Elsevier

    Dr. Fabian Schumacher, Robin Michelet

  35. Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic review

    Article • BMJ Open, January 2022, BMJ

    Robin Michelet

  36. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients

    Article • Clinical Pharmacokinetics, December 2021, Springer Science + Business Media

    Robin Michelet

  37. Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing—A Translational Example for Intensive Care Units

    Article • Pharmaceutics, December 2021, MDPI AG

    Robin Michelet

  38. No clinically relevant removal of meropenem by cytokine adsorber CytoSorb® in critically ill patients with sepsis or septic shock

    Article • Intensive Care Medicine, September 2021, Springer Science + Business Media

    Robin Michelet

  39. Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling

    Article • European Journal of Endocrinology, September 2021, Oxford University Press (OUP)

    Oliver Blankenstein, Robin Michelet

  40. 112P Prognostic impact of five serum biomarkers in patients with advanced non-small cell lung cancer (NSCLC): An exploratory analysis

    Article • Annals of Oncology, September 2021, Elsevier

    Robin Michelet

  41. Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics

    Article • Pharmaceutics, August 2021, MDPI AG

    Robin Michelet

  42. Cost-effectiveness of oral anticancer drugs and associated individualised dosing approaches in patients with cancer: protocol for a systematic review

    Article • BMJ Open, August 2021, BMJ

    Robin Michelet

  43. Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model

    Article • Cancers, June 2021, MDPI AG

    Robin Michelet

  44. CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications

    Article • Archives of Toxicology, May 2021, Springer Science + Business Media

    Robin Michelet

  45. Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli

    Article • Antibiotics, May 2021, MDPI AG

    Robin Michelet

  46. Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups

    Article • Cancers, May 2021, MDPI AG

    Robin Michelet

  47. Quantification of persister formation ofEscherichia colileveraging electronic cell counting and semi-mechanistic pharmacokinetic/pharmacodynamic modelling

    Article • Journal of Antimicrobial Chemotherapy, May 2021, Oxford University Press (OUP)

    Robin Michelet

  48. The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia

    Article • Pharmaceutics, April 2021, MDPI AG

    Dr Jean-Claude SIRARD, Robin Michelet

  49. Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients

    Article • Antibiotics, April 2021, MDPI AG

    Robin Michelet

  50. A Model-Based Pharmacokinetic/Pharmacodynamic Analysis of the Combination of Amoxicillin and Monophosphoryl Lipid A Against S. pneumoniae in Mice

    Article • Pharmaceutics, March 2021, MDPI AG

    Dr Jean-Claude SIRARD, Robin Michelet

  51. Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line

    Article • Cells, March 2021, MDPI AG

    Robin Michelet

  52. Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin

    Article • Pharmaceutical Research, March 2021, Springer Science + Business Media

    Robin Michelet

  53. Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies

    Article • Pharmaceuticals, February 2021, MDPI AG

    Robin Michelet

  54. Quantification of microdialysis related variability in humans: Clinical trial design recommendations

    Article • European Journal of Pharmaceutical Sciences, February 2021, Elsevier

    Robin Michelet

  55. Decoding (patho-)physiology of the lung by advanced in vitro models for developing novel anti-infectives therapies

    Article • Drug Discovery Today, January 2021, Elsevier

    Robin Michelet

  56. Correction to: Therapeutic drug monitoring of oral targeted antineoplastic drugs

    Article • European Journal of Clinical Pharmacology, December 2020, Springer Science + Business Media

    Robin Michelet

  57. Response to ‘Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia’

    Article • European Journal of Endocrinology, December 2020, Oxford University Press (OUP)

    Oliver Blankenstein, Robin Michelet

  58. Therapeutic drug monitoring of oral targeted antineoplastic drugs

    Article • European Journal of Clinical Pharmacology, November 2020, Springer Science + Business Media

    Robin Michelet

  59. Perspectives on Model‐Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations

    Article • Clinical Pharmacology & Therapeutics, October 2020, Wiley

    Robin Michelet

  60. Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children

    Article • European Journal of Endocrinology, October 2020, Oxford University Press (OUP)

    Oliver Blankenstein, Robin Michelet

  61. Desmopressin oral lyophilisate in young children: new insights in pharmacokinetics and pharmacodynamics

    Article • Archives of Disease in Childhood, July 2020, BMJ

    Robin Michelet

  62. Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach

    Article • Clinical Pharmacology & Therapeutics, July 2020, Wiley

    Robin Michelet

  63. Pediatric Pharmacology of Desmopressin in Children with Enuresis: A Comprehensive Review

    Article • Pediatric Drugs, June 2020, Springer Science + Business Media

    Robin Michelet

  64. Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia

    Article • The Journal of Clinical Endocrinology & Metabolism, March 2020, Endocrine Society

    Robin Michelet

  65. Boosting Toll-like receptor 4 signaling enhances the therapeutic outcome of antibiotic therapy in pneumococcal pneumonia

    Article • February 2020, Cold Spring Harbor Laboratory Press

    Dr Jean-Claude SIRARD, Robin Michelet

  66. Corrigendum to “Physiologically-Based Pharmacokinetic model for Ciprofloxacin in children with complicated Urinary Tract Infection” [European Journal of Pharmaceutical Sciences 128 (2019) 171–179]

    Article • European Journal of Pharmaceutical Sciences, February 2020, Elsevier

    Robin Michelet

  67. A rapid, simple and sensitive liquid chromatography tandem mass spectrometry assay to determine amoxicillin concentrations in biological matrix of little volume

    Article • Talanta, August 2019, Elsevier

    Dr Jean-Claude SIRARD, Robin Michelet

  68. An Integrated Paediatric Population PK/PD Analysis of dDAVP: How do PK Differences Translate to Clinical Outcomes?

    Article • Clinical Pharmacokinetics, July 2019, Springer Science + Business Media

    Robin Michelet

  69. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism

    Article • Drug Metabolism Reviews, June 2019, Taylor & Francis

    Gerd Mikus, Josefine Schulz, Robin Michelet

  70. Physiologically-Based Pharmacokinetic model for Ciprofloxacin in children with complicated Urinary Tract Infection

    Article • European Journal of Pharmaceutical Sciences, February 2019, Elsevier

    Robin Michelet

  71. The use of PBPK modeling across the pediatric age range using propofol as a case

    Article • Journal of Pharmacokinetics and Pharmacodynamics, October 2018, Springer Science + Business Media

    Robin Michelet, Professor karel allegaert

  72. Results of a Multicenter Population Pharmacokinetic Study of Ciprofloxacin in Children with Complicated Urinary Tract Infection

    Article • Antimicrobial Agents and Chemotherapy, July 2018, ASM Journals

    Robin Michelet

  73. PBPK in Preterm and Term Neonates: A Review

    Article • Current Pharmaceutical Design, February 2018, Bentham Science Publishers

    Robin Michelet

  74. Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis

    Article • European Journal of Clinical Pharmacology, December 2017, Springer Science + Business Media

    Robin Michelet

  75. O-9 Paediatric pbpk modelling of propofol using the middle out approach

    Article • Archives of Disease in Childhood, September 2017, BMJ

    Robin Michelet

  76. Modelling and sensitivity analysis of urinary platinum excretion in anticancer chemotherapy for the recovery of platinum

    Article • Sustainable Chemistry and Pharmacy, December 2016, Elsevier

    Professor Krist V. Gernaey, Robin Michelet

  77. Effects of Food and Pharmaceutical Formulation on Desmopressin Pharmacokinetics in Children

    Article • Clinical Pharmacokinetics, April 2016, Springer Science + Business Media

    Robin Michelet

  78. Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation

    Article • The AAPS Journal, July 2015, American Association of Pharmaceutical Scientists (AAPS)

    Professor karel allegaert , Robin Michelet